medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (4)

Diagnosis and treatment of febrile neutropenia in oncohematological patients

Barroso SG, Quintero SY, Rivas CYC

Language: Spanish
References: 20
Page: 1-17
PDF size: 278.83 Kb.


ABSTRACT

Introduction: Febrile neutropenia frequently affects patients with hematological malignancies and constitutes a medical emergency. Its therapeutic management is a real challenge at present, due to the appearance of infections caused by multiresistant microorganisms and the coexistence of patient- and treatment-dependent factors leading to risk for serious complications.
Methods: An exhaustive review was conducted about the topic in the main databases of the Virtual Health Library, for which papers mainly published in the last five years were used as reference.
Data analysis and synthesis: A diagnostic and therapeutic approach was applied to the study of patients at high risk for complications due to bacterial infections and their comprehensive evaluation. Recent tools to screen sepsis and sepsis-related organ damage are included which constitute mortality prediction elements in these patients.
Conclusions: Comprehensive management of febrile neutropenia includes not only a detailed clinical and humoral evaluation, but also the application of prognostic tools for risk stratification in each patient. Patient treatment should be started within the first hour after fever documentation, since infections may be rapidly progressive with a high risk for the development of sepsis, hemodynamic instability and multiple organ dysfunction.


REFERENCES

  1. Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut Bertrand A, Bergeron A, et al. European Conference on Infections in Leukemia. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33(4):844-2. DOI: http://10.1038/s41375-019-0388-x

  2. Keng MK, Sekeres MA. Febrile Neutropenia in Hematologic Malignancies. Curr Hematol Malign Rep. 2013; 8: 370-8. DOI: http://10.1007/s11899-013-0171-4

  3. Jaime Fagundo JC, Arencibia Núñez A, Gutiérrez Díaz A, Ramón Rodríguez L, Díaz Durán C. Urgencias en Hematología: alteraciones metabólicas y leucocitarias. Rev Cubana Hematol Inmunol Hemoter. 2012 Mar; 28(1):3-21.

  4. Vahedian-Ardakani HA, Moghimi M, Shayestehpour M, Doosti M, Amid N. Bacterial Spectrum and Antimicrobial Resistance Pattern in Cancer Patients with Febrile Neutropenia. Asian Pac J Cancer Prev. 2019 May 25;20(5):1471-4. DOI: http://10.31557/APJCP.2019.20.5.1471

  5. Calik S, Ari A, Bilgir O, Cetintepe T, Yis R, Sonmez U, et al. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. Saudi Med J. 2018 Sep;39(9):878-85. DOI: http://10.15537/smj.2018.9.22824

  6. Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. Virulence. 2016;7(3):280-97. DOI: http://10.1080/21505594.2016.1156821

  7. Sanz-Alonso MA, Carreras E. Manual práctico de hematología clínica. 6ª ed. Molins del Rei: Escofet Zamora; 2019

  8. Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Hentrich M, et al. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2019;98(5): 1051-69. DOI: http://10.1007/s00277-019-03622-0

  9. Lubwama M, Phipps W, Najjuka CF, Kajumbula H, Ddungu H, Kambugu JB, et al. Bacteremia in febrile cancer patients in Uganda. BMC Res Notes. 2019 Jul 30;12(1):464. DOI: http://10.1186/s13104-019-4520-9

  10. Ornelas-Sánchez M, Nuño-Vázquez L, Loera-Reyna A, Torres-Reyes D, Rivera-Gómez R, Sánchez A, et al. The »,» ®,® §,§ ­,­ ¹,¹ ²,² ³,³ ß,ß Þ,Þ þ,þ ×,× Ú,Ú ú,ú Û,Û û,û Ù,Ù ù,ù ¨,¨ Ü,Ü ü,ü Ý,Ý ý,ý ¥,¥ ÿ,ÿ ¶,¶ Golden Hour »,» ®,® §,§ ­,­ ¹,¹ ²,² ³,³ ß,ß Þ,Þ þ,þ ×,× Ú,Ú ú,ú Û,Û û,û Ù,Ù ù,ù ¨,¨ Ü,Ü ü,ü Ý,Ý ý,ý ¥,¥ ÿ,ÿ ¶,¶ : a capacity-building initiative to decrease life-threating complications related to neutropenic fever in patients with hematologic malignancies in low- and middle-income countries. Blood Adv. 2018 Nov;2(Suppl1):63-6. DOI: http://10.1182/bloodadvances.2018GS112240

  11. Heinz WJ, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol., 2017; 96(11):1775-9.

  12. Liu VX, Fielding Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am J Resp Crit Care Med. 2017; 196(7):856-63. DOI: http://10.1164/rccm.201609-1848OC

  13. Tan BH, Guzman MRT, Donato LKS, Kalimuddin S, Lee WHL, Tan AL, Wong GC. Impact of an alternating first-line antibiotics strategy in febrile neutropenia. PLoSOne. 2018 Nov;13(11):e0208039. DOI: http://10.1371/journal.pone.0208039

  14. Demirel A, Tabak F, Ar MC, Mete B, Öngören S, Yemisen M, et al. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. Turk J Haematol. 2015 Sep; 32(3):243-50. DOI: http://10.4274/tjh.2013.0422

  15. Rasmy A, Amal A, Fotih S, Selwi W. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J Cancer Prev Curr Res. 2016; 5(3): 00165. DOI: http://10.15406/jcpcr.2016.05.001655

  16. Ahangarzadeh Rezaee M, Abdinia B, Delpak A, Rezamand A. The Microbiologic Pattern in Pediatric Cancer Patients with Febrile Neutropenia and Bacteremia: A Referral Hospital-Based Study in Northwest of Iran. Iran J Pediatr. 2017 ; 27(2):e9452. DOI: http://10.5812/ijp.94522

  17. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:801-10. DOI: http://10.1001/jama.2016.0287

  18. Fernando SM, Tran A, Taljaard M, Cheng W, Rochwerg B, Seely AJE, et al. Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection. Ann Intern Med. 2018; 168:266-311. DOI: http://10.7326/M17-2820

  19. Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherché respiratoire en reanimation onco-hématologique study. J Clin Oncol. 2013;31:2810-8. DOI: http://10.1200/JCO.2012.47.2365

  20. Soares M, Bozza FA, Azevedo LCP, Silva UVA, Corrêa TD, Colombari F. Effects of organizational characteristics on outcomes and resource use in patients with cancer admitted to intensive care units. J Clin Oncol. 2016; 34:3315-24. DOI: http://10.1200/JCO.2016.66.9549




2020     |     www.medigraphic.com